Regen BioPharma Inc (RGBP)

[Airbrush19]

With regard to the remaining convertible debt outstanding ( “Remaining Notes”) it is the Company’s intent to enter into negotiations with the remaining noteholders to settle such obligations under such terms and conditions as to eliminate or severely limit potential dilution resulting from conversion of the Remaining Notes (“Settlement”).

No assurances can be provided that a Settlement by and between the Company and any or all holders of the Remaining Notes will be executed or, in the event a Settlement by and between the Company and any or all holders of the Remaining Notes is executed, such Settlement will be on terms and conditions favorable to the Company.